Elizabeth M Molyneux1, Queen Dube, Francis M Banda, Msandeni Chiume, Isaac Singini, Macpherson Mallewa, Edward C Schwalbe, Robert S Heyderman. 1. From the *Department of Pediatrics, College of Medicine, †Department of Pediatrics, Queen Elizabeth Central Hospital, and ‡John Hopkins Research Unit College of Medicine, Blantyre, Malawi; §Department of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom; ¶Malawi Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, Blantyre, Malawi; and ‖Division of Infection & Immunity, University College London, London, United Kingdom.
Abstract
BACKGROUND: The World Health Organization recommends benzylpenicillin and gentamicin as antimicrobial treatment for infants with sepsis in low-income settings, and ceftriaxone or cefotaxime as an alternative. In a meta-analysis from 13 low-income settings, Staphylococcus aureus, Klebsiella spp. and Escherichia coli accounted for 55% of infants with sepsis. In a review of bacterial meningitis, resistance to third generation cephalosporins was >50% of all isolates, and 44% of Gram-negative isolates were gentamicin resistant. However, ceftriaxone may cause neonatal jaundice, and gentamicin may cause deafness. Therefore, we compared parenteral benzylpenicillin plus gentamicin with ceftriaxone as first-line treatment, assessing outcome and adverse events. METHODS: This was an open randomized trial carried out in the Queen Elizabeth Central Hospital, Blantyre, Malawi, from 2010 to 2013. Infants <60 days of age with possible severe sepsis received either benzylpenicillin and gentamicin or ceftriaxone. Adverse events and outcomes were recorded until 6 months post discharge. RESULTS:Three-hundred forty-eight infants were included in analyses. Outcome in the benzylpenicillin and gentamicin and ceftriaxone groups was similar; deaths were 13.7% and 16.5% and sequelae were 14.5% and 11.2%, respectively. More infants in the penicillin/gentamicin group required phototherapy: 15% versus 5%, P = 0.03. Thirteen (6%) survivors had bilateral hearing loss. There was no difference between the treatment groups. By 6 months post discharge, 11 more infants had died, and 17 more children were found to have sequelae. CONCLUSIONS:Ceftriaxone and gentamicin are safe for infants in our setting. Infants should receive long-term follow-up as many poor outcomes occurred after hospital discharge.
RCT Entities:
BACKGROUND: The World Health Organization recommends benzylpenicillin and gentamicin as antimicrobial treatment for infants with sepsis in low-income settings, and ceftriaxone or cefotaxime as an alternative. In a meta-analysis from 13 low-income settings, Staphylococcus aureus, Klebsiella spp. and Escherichia coli accounted for 55% of infants with sepsis. In a review of bacterial meningitis, resistance to third generation cephalosporins was >50% of all isolates, and 44% of Gram-negative isolates were gentamicin resistant. However, ceftriaxone may cause neonatal jaundice, and gentamicin may cause deafness. Therefore, we compared parenteral benzylpenicillin plus gentamicin with ceftriaxone as first-line treatment, assessing outcome and adverse events. METHODS: This was an open randomized trial carried out in the Queen Elizabeth Central Hospital, Blantyre, Malawi, from 2010 to 2013. Infants <60 days of age with possible severe sepsis received either benzylpenicillin and gentamicin or ceftriaxone. Adverse events and outcomes were recorded until 6 months post discharge. RESULTS: Three-hundred forty-eight infants were included in analyses. Outcome in the benzylpenicillin and gentamicin and ceftriaxone groups was similar; deaths were 13.7% and 16.5% and sequelae were 14.5% and 11.2%, respectively. More infants in the penicillin/gentamicin group required phototherapy: 15% versus 5%, P = 0.03. Thirteen (6%) survivors had bilateral hearing loss. There was no difference between the treatment groups. By 6 months post discharge, 11 more infants had died, and 17 more children were found to have sequelae. CONCLUSIONS:Ceftriaxone and gentamicin are safe for infants in our setting. Infants should receive long-term follow-up as many poor outcomes occurred after hospital discharge.
Authors: F-M-R Maoulainine; N-S Elidrissi; G Chkil; F Abba; N Soraa; L Chabaa; M Amine; A Aboussad Journal: Arch Pediatr Date: 2014-06-30 Impact factor: 1.180
Authors: Amanda Gwee; Benjamin Coghlan; Dean Everett; Newton Chagoma; Amos Phiri; Lorna Wilson; Elizabeth Molyneux Journal: BMJ Open Date: 2012-05-15 Impact factor: 2.692
Authors: Nicholas A Feasey; Dean Everett; E Brian Faragher; Arantxa Roca-Feltrer; Arthur Kang'ombe; Brigitte Denis; Marko Kerac; Elizabeth Molyneux; Malcolm Molyneux; Andreas Jahn; Melita A Gordon; Robert S Heyderman Journal: PLoS Negl Trop Dis Date: 2015-07-31
Authors: Ming Ying Gan; Wen Li Lee; Bei Jun Yap; Shu Ting Tammie Seethor; Rachel G Greenberg; Jen Heng Pek; Bobby Tan; Christoph Paul Vincent Hornik; Jan Hau Lee; Shu-Ling Chong Journal: Front Pediatr Date: 2022-06-03 Impact factor: 3.569
Authors: Cían J Henry; Gergana Semova; Ellen Barnes; Isabel Cotter; Tara Devers; Aisyah Rafaee; Andreea Slavescu; Niamh O Cathain; Danielle McCollum; Edna Roche; David Mockler; John Allen; Judith Meehan; Claus Klingenberg; Jos M Latour; Agnes van den Hoogen; Tobias Strunk; Eric Giannoni; Luregn J Schlapbach; Marina Degtyareva; Frans B Plötz; Willem P de Boode; Lars Naver; James L Wynn; Helmut Küster; Jan Janota; Fleur M Keij; Irwin K M Reiss; Joseph M Bliss; Richard Polin; Joyce M Koenig; Mark A Turner; Christopher Gale; Eleanor J Molloy Journal: Pediatr Res Date: 2022-01-07 Impact factor: 3.953
Authors: J Seni; A A Mwakyoma; F Mashuda; R Marando; M Ahmed; R DeVinney; J D D Pitout; S E Mshana Journal: BMC Pediatr Date: 2019-01-26 Impact factor: 2.125